Epigenetic Mechanisms in Alzheimer's Disease

Introduction

Overview

Epigenetic mechanisms — heritable changes in gene expression without alterations to the underlying DNA sequence — have emerged as critical players in Alzheimer’s Disease (AD) pathogenesis. These mechanisms include DNA methylation, histone modifications, chromatin remodeling, non-coding RNA regulation, and RNA modifications. The dynamic and potentially reversible nature of epigenetic modifications makes them attractive therapeutic targets, unlike fixed genetic mutations ^{1"An epigenetic blockade of cognitive functions in the neurodegenerating brain"2012 · Nature · PMID ‘22388814’Open reference}.

AD exhibits global epigenetic alterations, with evidence of both hypermethylation and hypomethylation at different genomic loci. The complex pattern of epigenetic dysregulation reflects the interaction between genetic susceptibility (particularly APOE become hypomethylated and transcriptionally reactivated in AD, contributing to genomic instability, double-strand DNA breaks, and activation of the cGAS-STING] innate immune pathway through cytosolic DNA accumulation ^{2"Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements"2018 · Cell Rep · PMID ‘30591447’Open reference}.

DNA Methylation in Alzheimer’s Disease

DNA methylation — the addition of methyl groups to cytosine residues in CpG dinucleotides — is the most studied epigenetic modification in AD. Genome-wide studies have identified widespread DNA methylation changes in AD brain and blood tissue

Differential Methylation in AD Brain

The landmark 2014 study by De Jager et al. was the first to perform epigenome-wide association analysis (EWAS) in AD brain cortex, identifying differentially methylated positions (DMPs) at multiple loci including ANK1, BIN1, RHBDF2, and ABCA1 ^{3"‘Alzheimer’’s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci’"2014 · Nat Neurosci · PMID ‘25129075’Open reference}. Subsequent studies confirmed these findings and expanded the list of altered loci across multiple brain regions ^{4"A meta-analysis of epigenome-wide association studies in Alzheimer’s Disease highlights novel differentially methylated loci across cortex"2024 · Nat Neurosci · PMID ‘38688285’Open reference, 5"Distinct DNA methylation changes in Alzheimer’s disease brains and blood"2018 · J Neurosci Res · PMID ‘30004639’Open reference}. ANK1 (ankyrin repeat domain 1) shows some of the most consistent hypermethylation in AD, particularly in the hippocampus and entorhinal cortex — regions most vulnerable to neurodegeneration.

Blood-Based DNA Methylation Biomarkers

Several studies have identified DNA methylation signatures in blood that correlate with AD pathology and can serve as accessible biomarkers.Hernandez et al. demonstrated distinct blood DNA methylation patterns in AD patients compared to controls, with some overlap with brain changes ^{5"Distinct DNA methylation changes in Alzheimer’s disease brains and blood"2018 · J Neurosci Res · PMID ‘30004639’Open reference}. Lord et al. showed that epigenetic age acceleration — where DNA methylation-based age exceeds chronological age — is associated with increased AD risk and faster cognitive decline ^{6"DNA methylation age is accelerated in Alzheimer’s disease"2020 · Aging Cell · PMID ‘32654153’Open reference}. This finding suggests that accelerated biological aging, as measured by epigenetic clocks, may be a modifiable risk factor for AD.

Tau-Mediated Epigenetic Changes

Tau pathology itself can drive epigenetic alterations. Guo et al. demonstrated that tau induces genome-wide promoter DNA methylation changes in AD, providing a mechanistic link between tau pathology and transcriptional dysregulation ^{2"Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements"2018 · Cell Rep · PMID ‘30591447’Open reference}. These findings were extended by Song et al. who explored the specific role of DNA methylation in tauopathies and AD progression ^{7"The role of DNA methylation in tauopathies and Alzheimer’s disease"2023 · Prog Neuropsychopharmacol Biol Psychiatry · PMID ‘37061765’Open reference}.

Histone Modifications in Alzheimer’s Disease

Histone modifications alter chromatin structure through acetylation, methylation, phosphorylation, ubiquitination, SUMOylation, and other post-translational modifications. These changes regulate gene expression by modifying histone-DNA interactions or recruiting chromatin-binding effector proteins ^{8"Epigenetic regulation of synaptic plasticity and memory"2012 · Cell · PMID ‘22846637’Open reference}.

Histone Acetylation

Histone acetylation, mediated by histone acetyltransferases (HATs: CBP/p300, GCN5, Tip60), neutralizes the positive charge of lysine residues, relaxing chromatin and promoting transcription. HDAC enzymes remove acetyl groups, generally promoting chromatin compaction and transcriptional repression. In AD, altered HDAC/HAT balance contributes to transcriptional dysregulation and cognitive deficits.

Rao et al. demonstrated significantly increased acetylation of histone H3 in AD brain tissue, particularly in the hippocampus ^{9"Increased acetylation of histone H3 in Alzheimer’s disease brain"2012 · Neurobiol Aging · PMID ‘21764257’Open reference}. This altered acetylation pattern correlates with changes in gene expression related to synaptic plasticity and neuronal function. Karat et al. further confirmed global changes in both histone acetylation and methylation in AD brains ^{2"Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements"2018 · Cell Rep · PMID ‘30591447’Open reference}0.

HDAC2 is significantly overexpressed in AD brains, particularly in hippocampus and entorhinal cortex — regions vulnerable to early pathology ^{2"Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements"2018 · Cell Rep · PMID ‘30591447’Open reference}1. HDAC2 binds to promoters of synaptic plasticity genes (including those encoding AMPA and NMDA receptor receptor subunits, BDNF, and CaMKII), repressing their transcription and contributing to memory impairment. Aβ oligomers induce HDAC2 upregulation through a glucocorticoid receptor-mediated pathway.

Marathe et al. documented altered HDAC expression in temporal cortex and hippocampus in AD, with specific changes in HDAC2 and other Class I HDACs ^{2"Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements"2018 · Cell Rep · PMID ‘30591447’Open reference}2. Wen et al. reviewed the therapeutic potential of HDAC inhibitors in AD, highlighting both the promise and challenges of this approach ^{2"Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements"2018 · Cell Rep · PMID ‘30591447’Open reference}3.

H4K16 acetylation (H4K16ac) is globally reduced in AD brain tissue. H4K16ac is a key mark for maintaining euchromatin and preventing heterochromatin spreading. Its loss leads to silencing of neuronal genes and reactivation of normally repressed genomic regions.

Sun et al. demonstrated specific epigenetic regulation of histone modifications and glutaminase 1 expression in AD brain, linking epigenetic changes to metabolic alterations ^{2"Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements"2018 · Cell Rep · PMID ‘30591447’Open reference}4. Goodman et al. showed that HDAC inhibitor effects on memory require BDNF expression, providing a mechanistic link between histone acetylation and neuronal function ^{2"Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements"2018 · Cell Rep · PMID ‘30591447’Open reference}5.

Pharmacological HDAC inhibition reverses cognitive deficits in mouse models of AD, restoring expression of synaptic plasticity genes and improving memory performance. Saab et al. demonstrated that histone modifications and specific histone deacetylases are required for memory formation ^{2"Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements"2018 · Cell Rep · PMID ‘30591447’Open reference}6. However, broad-spectrum HDAC inhibitors (such as SAHA/vorinostat, valproic acid, and sodium butyrate) cause undesirable side effects including immunosuppression and cardiac toxicity, driving interest in isoform-selective inhibitors targeting HDAC2 or HDAC6 specifically.

Histone Methylation

Histone methylation can activate or repress transcription depending on the modified residue and degree of methylation:

• H3K4me3 (activating): Altered at genes involved in neuronal survival and synaptic function. Loss of H3K4me3 at BDNF and Arc promoters correlates with reduced expression and cognitive decline.

• H3K9me3 (repressive): Loss of repressive H3K9me3 marks leads to aberrant re-expression of developmental genes in AD neurons — a phenomenon termed “epigenetic derepression” that contributes to cell cycle re-entry, a recognized pathway to neuronal death ^{2"Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements"2018 · Cell Rep · PMID ‘30591447’Open reference}7.

• H3K27me3 (repressive, Polycomb-mediated): Shows complex redistributive patterns in AD, with loss at neuronal identity genes and gain at synaptic genes. EZH2, the methyltransferase responsible for H3K27me3, is dysregulated in AD.

• H3K36me2: Increased at inflammatory gene promoters in AD microglia shows altered expression and binding patterns in AD, affecting genes critical for neuronal function. BAF complex (a SWI/SNF variant) subunit composition shifts in AD neurons, reducing neuronal-specific nBAF complexes while increasing progenitor-associated npBAF complexes, potentially reflecting dedifferentiation.

Three-dimensional chromatin architecture, including topologically associating domains (TADs) and chromatin loops, is disrupted in AD ^{2"Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements"2018 · Cell Rep · PMID ‘30591447’Open reference}8. Hi-C and ATAC-seq studies in AD brain nuclei have identified AD-specific chromatin interaction patterns affecting genes involved in APP processing, tau] phosphorylation, and neuroinflammation. Enhancer-promoter loop rewiring brings distal enhancers containing AD GWAS risk variants into contact with target genes, providing a mechanistic link between non-coding genetic risk variants and gene expression changes.

CTCF (CCCTC-binding factor), the primary architectural protein defining TAD boundaries, shows reduced binding in AD hippocampus. Loss of CTCF boundary function leads to inappropriate enhancer-promoter contacts and aberrant gene activation, potentially contributing to the transcriptional chaos observed in advanced AD.

Non-Coding RNAs in Alzheimer’s Disease

MicroRNAs

MicroRNAs (miRNAs) are small (20–22 nucleotide) non-coding RNAs that regulate gene expression by guiding the RNA-induced silencing complex (RISC) to complementary sequences in the 3’UTR of target mRNAs, leading to translational repression or mRNA degradation. Specific miRNA signatures distinguish AD from control brains and correlate with neuropathological changes ^{2"Tau induces genome-wide DNA hypomethylation and reactivation of transposable elements"2018 · Cell Rep · PMID ‘30591447’Open reference}9.

Geigl et al. reviewed circulating miRNAs as biomarkers for AD, highlighting their potential for non-invasive diagnosis ^{3"‘Alzheimer’’s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci’"2014 · Nat Neurosci · PMID ‘25129075’Open reference}0. Satoh et al. performed microarray analysis identifying specific miRNA expression profiles in AD brains ^{3"‘Alzheimer’’s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci’"2014 · Nat Neurosci · PMID ‘25129075’Open reference}1. Kumar et al. demonstrated that circulating miRNA signatures in blood can reflect brain pathology in AD, providing a link between peripheral biomarkers and central nervous system changes ^{3"‘Alzheimer’’s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci’"2014 · Nat Neurosci · PMID ‘25129075’Open reference}2.

Key AD-associated miRNAs:

• miR-132: The most consistently downregulated miRNA in AD brain. miR-132 targets tau kinase GSK3β, the splicing factor PTBP2, and FOXO3a. Its loss leads to increased tau phosphorylation, altered tau splicing (favoring 4R tau), and impaired autophagy. miR-132 supplementation reverses tau pathology in mouse models.

• miR-146a: Upregulated in AD brain and CSF. Targets complement factor H (CFH) and TRAF6, promoting neuroinflammation and complement-mediated synaptic loss.

• miR-125b: Overexpressed in AD, promotes tau hyperphosphorylation by targeting DUSP6 and PPP1CA phosphatases.

• miR-29a/b-1: Downregulated in AD and directly targets BACE1.

Long Non-Coding RNAs and Circular RNAs

Beyond miRNAs, other non-coding RNAs are implicated in AD. Leggio et al. explored lncRNAs and circular RNAs as potential biomarkers in AD ^{3"‘Alzheimer’’s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci’"2014 · Nat Neurosci · PMID ‘25129075’Open reference}3. van den Boom et al. specifically investigated circular RNAs as novel biomarkers in AD ^{3"‘Alzheimer’’s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci’"2014 · Nat Neurosci · PMID ‘25129075’Open reference}4. Zhou et al. reviewed the role of lncRNAs in synaptic dysfunction in AD ^{3"‘Alzheimer’’s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci’"2014 · Nat Neurosci · PMID ‘25129075’Open reference}5.

N6-Methyladenosine (m6A)

N6-methyladenosine (m6A) is the most abundant internal modification on eukaryotic mRNA, regulating mRNA splicing, export, translation, and stability. m6A is installed by “writers” (METTL3/METTL14/WTAP complex), removed by “erasers” (FTO, ALKBH5), and interpreted by “readers” (YTHDF1/2/3, YTHDC1/2) ^{3"‘Alzheimer’’s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci’"2014 · Nat Neurosci · PMID ‘25129075’Open reference}6.

In the normal brain, m6A sites increase with age, predominantly within the 3’UTR of transcripts encoding synaptic proteins. However, this age-dependent m6A increase is disrupted in AD. METTL3, the catalytic m6A methyltransferase, shows significantly reduced expression in AD hippocampus neurons. METTL3 knockdown in mice causes memory deficits, synaptic loss, and neuronal death, demonstrating a causal role ^{3"‘Alzheimer’’s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci’"2014 · Nat Neurosci · PMID ‘25129075’Open reference}7.

A 2025 study revealed that m6A modification of promoter-antisense RNAs (paRNAs) is profoundly rewired in AD brains, affecting 3D chromatin organization and neuronal gene regulation. This connects epitranscriptomic changes directly to chromatin architecture disruption in AD ^{3"‘Alzheimer’’s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci’"2014 · Nat Neurosci · PMID ‘25129075’Open reference}8.

m6A also regulates the expression of tau: m6A modification of MAPT mRNA influences its stability and translation. Changes in m6A at specific MAPT mRNA positions may contribute to the altered tau isoform ratios observed in AD. The m6A reader YTHDF2, which promotes mRNA degradation, is reduced in AD, potentially contributing to the increased stability of pathogenic transcripts.

Other RNA Modifications

Beyond m6A, other RNA modifications are emerging as relevant to AD:

• 5-methylcytosine (m5C) on tRNA and mRNA: Regulated by NSUN2; loss of NSUN2 causes neurodegeneration in animal models.

• Pseudouridine (Ψ): The most common RNA modification; changes in pseudouridylation of rRNA may impair translation fidelity in AD neurons.

• A-to-I RNA editing by ADAR enzymes: Editing of glutamate receptor (GluA2) mRNA is critical for neuronal survival; altered editing patterns are reported in AD.

Epigenetic Clocks and Biological Age

DNA methylation-based epigenetic clocks (Horvath clock, Hannum clock, GrimAge, DunedinPACE) provide estimates of biological age that predict mortality and morbidity better than chronological age. Epigenetic age acceleration — when biological age exceeds chronological age — is consistently associated with increased AD risk and faster cognitive decline ^{3"‘Alzheimer’’s Disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci’"2014 · Nat Neurosci · PMID ‘25129075’Open reference}9.

The GrimAge clock, which incorporates methylation surrogates for plasma proteins and smoking pack-years, shows the strongest associations with AD neuropathology and incident dementia. DunedinPACE, measuring the pace of biological aging, demonstrates that faster aging rates predict amyloid accumulation and hippocampal atrophy in cognitively normal individuals. These findings suggest that interventions slowing biological aging (as measured by epigenetic clocks) could reduce AD risk.

Brain-specific epigenetic clocks reveal that the AD cortex is biologically older than expected, with the degree of epigenetic age acceleration correlating with Braak staging and cognitive impairment. Clinical trials of SAM or B-vitamin supplementation for AD prevention have yielded mixed results, possibly due to intervention timing.

Exercise and Epigenetic Reprogramming

Physical exercise improves cognitive function and reduces AD risk partly through epigenetic mechanisms. Exercise induces DNA hypomethylation at synaptic plasticity gene promoters (BDNF, ARC, HOMER1), increases histone H3 acetylation in the hippocampus, and elevates expression of HATs while reducing HDAC2 levels. Aerobic exercise also increases blood levels of the myokine irisin, which crosses the Blood-Brain Barrier and promotes BDNF expression through epigenetic derepression.

Early-Life Programming

The Developmental Origins of Health and Disease (DOHaD) hypothesis extends to AD. Maternal nutrition, stress, and environmental toxin exposure during pregnancy influence offspring brain development through epigenetic programming. Lead (Pb) exposure in early life causes persistent DNA methylation changes at AD-related genes (APP, BACE1 in offspring, with effects persisting into adulthood and increasing vulnerability to neurodegeneration.

Therapeutic Approaches

HDAC Inhibitors

Histone deacetylase inhibitors represent the most advanced epigenetic therapy for AD ^{4"A meta-analysis of epigenome-wide association studies in Alzheimer’s Disease highlights novel differentially methylated loci across cortex"2024 · Nat Neurosci · PMID ‘38688285’Open reference, 5"Distinct DNA methylation changes in Alzheimer’s disease brains and blood"2018 · J Neurosci Res · PMID ‘30004639’Open reference}0:

• Pan-HDAC inhibitors: Vorinostat (SAHA), sodium butyrate, and valproic acid improve cognition in AD mouse models but have dose-limiting toxicity in humans.

• HDAC2-selective inhibitors: BRD6688 and other HDAC2-selective compounds show improved safety profiles while maintaining efficacy in preclinical models. HDAC2 selectivity is challenging due to high structural similarity among Class I HDACs.

• HDAC6 inhibitors: Tubastatin A and ACY-1215 (ricolinostat) inhibit the cytoplasmic HDAC6, which deacetylates tau (promoting aggregation) and α-tubulin (impairing axonal transport). HDAC6 inhibition reduces tau pathology and restores axonal transport in AD models.

Poulogiannis et al. reviewed epigenetic therapy approaches specifically for AD, discussing both opportunities and challenges ^{4"A meta-analysis of epigenome-wide association studies in Alzheimer’s Disease highlights novel differentially methylated loci across cortex"2024 · Nat Neurosci · PMID ‘38688285’Open reference, 5"Distinct DNA methylation changes in Alzheimer’s disease brains and blood"2018 · J Neurosci Res · PMID ‘30004639’Open reference}1. Bhatia et al. explored epigenetic modulation of autophagy in AD, highlighting another therapeutic pathway ^{4"A meta-analysis of epigenome-wide association studies in Alzheimer’s Disease highlights novel differentially methylated loci across cortex"2024 · Nat Neurosci · PMID ‘38688285’Open reference, 5"Distinct DNA methylation changes in Alzheimer’s disease brains and blood"2018 · J Neurosci Res · PMID ‘30004639’Open reference}2.

DNMT Modulators

DNA methyltransferase inhibitors (5-azacytidine, decitabine) are FDA-approved for myelodysplastic syndromes and could theoretically correct hypermethylation at AD-relevant loci. However, their lack of locus specificity and potential toxicity limit CNS application. Low-dose decitabine showed neuroprotective effects in AD mouse models by demethylating BDNF and synaptic gene promoters.

Epigenome Editing

CRISPR-based epigenome editing tools — dCas9 fused to DNMT3A (for targeted methylation), TET1 (for targeted demethylation), or p300 (for targeted acetylation) — enable precise modification of epigenetic marks at specific genomic loci without altering the DNA sequence. These technologies offer the potential to correct pathological epigenetic alterations with locus specificity that small molecules cannot achieve. AAV vectors carrying epigenome editors have been tested in preclinical models, with CRISPR-dCas9-TET1 successfully demethylating and reactivating silenced BDNF in AD mouse hippocampus ^{4"A meta-analysis of epigenome-wide association studies in Alzheimer’s Disease highlights novel differentially methylated loci across cortex"2024 · Nat Neurosci · PMID ‘38688285’Open reference, 5"Distinct DNA methylation changes in Alzheimer’s disease brains and blood"2018 · J Neurosci Res · PMID ‘30004639’Open reference}3. Brain delivery and off-target editing remain key challenges.

miRNA-Based Therapeutics

Synthetic miR-132 mimics delivered via lipid nanoparticles or AAV vectors reduce tau pathology and improve cognition in AD mouse models. Anti-miRNA oligonucleotides targeting upregulated miRNAs (miR-146a, miR-125b) are in preclinical development. The success of nusinersen and other antisense oligonucleotide therapies for neurodegenerative diseases provides a translational framework for CNS-targeted RNA therapeutics.

Lifestyle Interventions

Non-pharmacological interventions including exercise, cognitive training, Mediterranean diet, and stress reduction (meditation, yoga) modify epigenetic marks relevant to AD. The FINGER trial demonstrated that a multidomain lifestyle intervention improved cognition in at-risk individuals, and sub-studies suggest epigenetic mechanisms contribute to these benefits. These approaches offer low-risk strategies for AD prevention, potentially working through cumulative epigenetic reprogramming.

Gene Therapy Approaches

Emerging genetic therapies offer additional pathways for AD treatment:

• Antisense Oligonucleotides (ASOs): IONIS-MAPT is an ASO targeting MAPT mRNA in Alzheimer’s Disease, showing safety and biomarker effects in healthy volunteers.

• AAV Vectors: Clinical trials using AAV2-GAD for Parkinson’s Disease and AAVrh.10 delivering AADC demonstrate the potential for gene therapy approaches in neurodegeneration.

• CRISPR/Cas9 Genome Editing: Base editing and prime editing offer potential for precise genetic correction, though delivery challenges remain significant for CNS applications.

Biomarker Potential

Epigenetic biomarkers offer several advantages for AD diagnosis and monitoring:

• Blood DNA methylation: Differentially methylated positions in blood (particularly at ANK1, HOXA3, BIN1) reflect brain methylation changes and correlate with AD diagnosis. Methylation arrays on blood DNA provide a cost-effective screening approach.

• miRNA panels: Multi-miRNA panels in CSF and blood demonstrate high diagnostic accuracy for AD and can distinguish AD from other dementias. Exosome-encapsulated miRNAs are stable in blood and may better reflect brain miRNA profiles.

• Epigenetic age acceleration: GrimAge and DunedinPACE acceleration predict incident AD and could identify individuals for prevention trials.

• Histone modification profiling: Circulating nucleosomes carrying specific histone marks (H3K9me3, H3K27ac) are detectable in blood and are under investigation as AD biomarkers.

Recent Research Updates (2024-2026)

Recent advances in epigenetics research have revealed new mechanisms in Alzheimer’s disease:

• Peripheral immunity epigenetics: Epigenetic dysregulation in Alzheimer’s disease affects peripheral immunity, with DNA methylation changes in immune cells correlating with disease progression^{4"A meta-analysis of epigenome-wide association studies in Alzheimer’s Disease highlights novel differentially methylated loci across cortex"2024 · Nat Neurosci · PMID ‘38688285’Open reference, 5"Distinct DNA methylation changes in Alzheimer’s disease brains and blood"2018 · J Neurosci Res · PMID ‘30004639’Open reference}4.

• Genetics and epigenetics integration: Integrated genetic and epigenetic analyses provide a comprehensive understanding of AD pathogenesis, revealing novel risk genes and regulatory mechanisms^{4"A meta-analysis of epigenome-wide association studies in Alzheimer’s Disease highlights novel differentially methylated loci across cortex"2024 · Nat Neurosci · PMID ‘38688285’Open reference, 5"Distinct DNA methylation changes in Alzheimer’s disease brains and blood"2018 · J Neurosci Res · PMID ‘30004639’Open reference}5.

• Epigenetics in neurodegeneration: Epigenetic modifications including DNA methylation, histone acetylation, and non-coding RNAs play crucial roles in neurodegenerative disease progression^{4"A meta-analysis of epigenome-wide association studies in Alzheimer’s Disease highlights novel differentially methylated loci across cortex"2024 · Nat Neurosci · PMID ‘38688285’Open reference, 5"Distinct DNA methylation changes in Alzheimer’s disease brains and blood"2018 · J Neurosci Res · PMID ‘30004639’Open reference}6.

^{4"A meta-analysis of epigenome-wide association studies in Alzheimer’s Disease highlights novel differentially methylated loci across cortex"2024 · Nat Neurosci · PMID ‘38688285’Open reference, 5"Distinct DNA methylation changes in Alzheimer’s disease brains and blood"2018 · J Neurosci Res · PMID ‘30004639’Open reference}7: Epigenetic dysregulation in Alzheimer’s disease peripheral immunity. Nat Commun 2024. ^{4"A meta-analysis of epigenome-wide association studies in Alzheimer’s Disease highlights novel differentially methylated loci across cortex"2024 · Nat Neurosci · PMID ‘38688285’Open reference, 5"Distinct DNA methylation changes in Alzheimer’s disease brains and blood"2018 · J Neurosci Res · PMID ‘30004639’Open reference}8: Genetics and Epigenetics of Alzheimer’s Disease: Understanding Pathogenesis. Mol Psychiatry 2025. ^{4"A meta-analysis of epigenome-wide association studies in Alzheimer’s Disease highlights novel differentially methylated loci across cortex"2024 · Nat Neurosci · PMID ‘38688285’Open reference, 5"Distinct DNA methylation changes in Alzheimer’s disease brains and blood"2018 · J Neurosci Res · PMID ‘30004639’Open reference}9: Epigenetics in Neurodegenerative Diseases. Nat Rev Neurosci 2025.

External Links

• PubMed) — Biomedical literature

• Roadmap Epigenomics Project — Reference epigenomes

• ENCODE — Encyclopedia of DNA elements

• Allen Brain Atlas — Brain gene expression data

Background

The study of Epigenetic Mechanisms In Alzheimer’s Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration/mechanisms) and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [BACE1

• Alzheimer’s Disease

• Amyloid-Beta Aggregation

• Tau Pathology

• Parkinson’s Disease

• ALS

• neuroinflammation

• Microglia

• Autophagy

• Proteostasis Failure

Confidence Assessment

🟡 Moderate Confidence

Overall Confidence: 50%

Epigenetic Mechanisms in AD

flowchart TD
    A["Environmental Factors"]  -->  B["DNA Methylation"]
    A  -->  C["Histone Modification"]
    A  -->  D["non-coding RNA"]
    
    B  -->  E["Gene Expression Changes"]
    C  -->  E
    D  -->  E
    
    E  -->  F["Amyloid Production"]
    E  -->  G["Tau Hyperphosphorylation"]
    E  -->  H["Synaptic Dysfunction"]
    E  -->  I["Neuroinflammation"]
    
    F  -->  J["AD Pathology"]
    G  -->  J
    H  -->  J
    I  -->  J

Histone Modifications

flowchart TB
    A["Histone Tail"] --> B["Acetylation"]
    A --> C["Methylation"]
    A --> D["Phosphorylation"]
    A --> E["Ubiquitination"]
    
    B --> F["up Gene Transcription"]
    C --> G{"Type"}
    G -->|"H3K4me3"| H["Gene Activation"]
    G -->|"H3K9me3"| I["Gene Silencing"]
    D --> J["DNA Damage Response"]
    E --> K["Protein Degradation"]